Increasing colorectal polyp size has been consistently associated with a higher risk of invasive colorectal cancer [1–4]. Recent studies have focused on the prevalence of cancer in polyps < 10 mm in size, and have identified a lower risk of invasive cancer compared with earlier studies [5–11]. Some recent studies have investigated this issue to determine the feasibility of a “resect and discard” strategy for diminutive polyps [7–9], as the prevalence of cancer in diminutive and small polyps is a determinant of the appropriateness of a resect and discard paradigm.

Declining rates of cancer in small and diminutive polyps may reflect improved optics in colonoscopes that expose large numbers of low-volume, flat adenomas with a much lower risk of cancer [12–14] compared with the larger-volume polyps detectable with lower resolution and fiberoptic instruments used in older studies.

The anticipated risk of cancer in polyps ≥ 10 mm is also of importance to endoscopists, as polyps with a greater risk of cancer are optimally resected en bloc [15]. Thus, the risk of cancer may affect the resection approach. Furthermore, resected polyps with a higher cancer risk should be handled properly by the endoscopist and pathologist, so as to ensure proper orientation and optimal pathological assessment. Several studies have focused on cancer risk in colorectal polyps ≥ 20 mm [8,16–17]. Although some studies have reported the risk of cancer in polyps 10–19 mm in size [8,16–18], we considered that it would be useful to update the prevalence of cancer in polyps in this size range, as polyps of this size are common and this
issue has not been extensively studied using modern colonoscopes (Table 1). We now report the largest study to address this issue.

**Methods**

We reviewed and analyzed a prospectively created database of polyps identified in the Indiana University Hospital endoscopy unit between January 2001 and June 2016. We included consecutive colonoscopies performed during the study period with the exception of those performed in patients with inflammatory bowel disease or polyposis syndrome. Patients with any other screening, surveillance, and diagnostic indications for colonoscopy were included in the database. Permission to review the database was granted on 6 December 2017 by the Institutional Review Board of our institution.

The database included patient demographic details, name of the endoscopist who performed the examination, polyp size (as measured by endoscopist estimate), polyp location in the colon (by endoscopist estimate), polyp morphology (by endoscopist recognition), polyp pathology (as reported in the routine pathology report), and the method of resection (endoscopic vs. surgical). For the purpose of this study, polyps ≥10 mm in size were grouped by size: 10–19 mm and ≥20 mm.

Conventional adenomas were defined as those interpreted pathologically as tubular, tubulovillous, or villous adenomas. Serrated class lesions were defined as those interpreted as hyperplastic polyp, sessile serrated polyp, sessile serrated adenoma, serrated adenoma, and traditional serrated adenoma. Cancer was defined as submucosal invasion. Cancers other than adenocarcinomas of probable colonic origin were excluded. A total of 17 polyps ≥10 mm were excluded from the study because data were missing.

Endoscopic images of all lesions with cancer were reviewed by the senior author (D.K.R.) to determine whether the cancer was evident by endoscopic inspection alone. The endoscopist was blinded to whether the lesion had been resected endoscopically or surgically. Lesions were considered to have endoscopic evidence of cancer if they had areas of overt ulceration or areas of vascular disruption on the lesion surface.

Right colon location was defined as proximal to the splenic flexure (transverse colon, hepatic flexure, ascending colon, and cecum).

Descriptive statistical analysis was performed.

**Results**

During the study period, a total of 5093 lesions ≥10 mm were documented from 4112 endoscopies performed by 48 endoscopists in 4020 patients. The mean age of patients was 63.2 years (range 18–91) and 34.4% of patients were female.

A total of 189 polyps that were not considered conventional adenomas or serrated class lesions were excluded from further analysis. These included inflammatory polyps (n = 98), granulation tissue (n = 15), hamartoma (n = 14), carcinoid tumor (n = 6), and other lesions.

Descriptive statistical analysis was performed.

**Table 1** Previously reported data on rate of cancer in colorectal polyps ≥10 mm.

<table>
<thead>
<tr>
<th>Study [ref]</th>
<th>Cancer/Total polyps ≥10 mm, n (%)</th>
<th>Cancer/Total polyps 10–19 mm, n (%)</th>
<th>Cancer/Total polyps ≥20 mm, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burnikel et al., 1954 [19]</td>
<td>48/106 (45.3)</td>
<td>31/72 (43.1)</td>
<td>17/34 (50.0)</td>
</tr>
<tr>
<td>Wilson et al., 1955 [20]</td>
<td>_</td>
<td>_ (18.0)</td>
<td>_ (22.0)</td>
</tr>
<tr>
<td>Muto et al., 1975 [2]</td>
<td>253/1010 (25.0)</td>
<td>55/580 (9.5)</td>
<td>198/430 (46.0)</td>
</tr>
<tr>
<td>Shinya et al., 1979 [21]</td>
<td>275/4125 (6.7)</td>
<td>125/2738 (4.6)</td>
<td>150/1387 (10.8)</td>
</tr>
<tr>
<td>Matek et al., 1985 [22]</td>
<td>80/1277 (6.3)</td>
<td>45/906 (5.0)</td>
<td>35/371 (9.4)</td>
</tr>
<tr>
<td>Hermanek et al., 1987 [23]</td>
<td>659/2246 (2.9)</td>
<td>87/1164 (7.5)</td>
<td>572/1082 (52.9)</td>
</tr>
<tr>
<td>Pines et al., 1991 [24]</td>
<td>116/441 (26.3)</td>
<td>86/314 (27.4)</td>
<td>30/127 (23.6)</td>
</tr>
<tr>
<td>Aldridge et al., 2001 [26]</td>
<td>23/228 (10.1)</td>
<td>13/122 (10.7)</td>
<td>10/106 (9.4)</td>
</tr>
<tr>
<td>Fong et al., 2003 [27]</td>
<td>5/70 (7.1)</td>
<td>4/62 (6.5)</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>Odom et al., 2005 [18]</td>
<td>22/155 (14.2)</td>
<td>3/124 (2.4)</td>
<td>19/31 (61.3)</td>
</tr>
<tr>
<td>Lieberman et al., 2008 [16]</td>
<td>25/1154 (2.2)</td>
<td>16/963 (1.7)</td>
<td>9/191 (4.7)</td>
</tr>
<tr>
<td>Zafar et al., 2012 [17]</td>
<td>7/123 (5.7)</td>
<td>2/83 (2.4)</td>
<td>5/40 (12.5)</td>
</tr>
<tr>
<td>Gupta et al., 2012 [8]</td>
<td>1/286 (0.3)</td>
<td>0/242 (0)</td>
<td>1/44 (2.3)</td>
</tr>
<tr>
<td>Pooled data</td>
<td>1525/11286 (13.5)</td>
<td>473/7407 (6.4)</td>
<td>1052/3879 (27.1)</td>
</tr>
<tr>
<td>Our study</td>
<td>138/4904 (2.8)</td>
<td>28/3068 (0.9)</td>
<td>110/1836 (6.0)</td>
</tr>
</tbody>
</table>

* Wilson et al., is excluded from the pooled analysis as the actual numbers were not reported.
metastatic cancer (n = 7), granular cell tumor (n = 45), neuroendocrine tumor (n = 3), and sarcomatoid lesions (n = 1) (Fig. 1).

Table 2 shows the lesion size and histology including the prevalence of cancer. Of the lesions included in the study, 3068 (62.6%) were 10–19 mm and 1836 (37.4%) were ≥20 mm. Among the 3068 lesions 10–19 mm in size, there were 1997 (65.1%) conventional adenomas, of which 1547 (77.5%) were tubular adenomas, 421 (21.1%) were tubulovillous adenomas, 4 (0.2%) were villous adenomas, and 25 (1.2%) polyps had cancer. There were 1071 (34.9%) serrated class lesions, of which 389 (36.3%) were sessile serrated polyps, 679 (63.4%) were hyperplastic polyps, and 3 (0.3%) had cancer. Thus, among all 3068 lesions 10–19 mm in size, 28 (0.9%) had cancer.

There was no difference between the prevalence of cancer in lesions of 10–19 mm that were located in the right colon vs. the left colon (14/1813 [0.8%] vs. 14/1255 [1.1%]; P = 0.33).

Among the 1836 lesions ≥20 mm in size, there were 1487 (81.0%) conventional adenomas, of which 721 (48.5%) were tubular adenomas, 644 (43.3%) were tubulovillous adenomas, 19 (1.3%) were villous adenomas, and 103 lesions (6.9%) had cancer. There were 349 (19.0%) lesions ≥20 mm in size in the serrated class, of which 194 (55.6%) were sessile serrated polyps, 148 (42.4%) were hyperplastic polyps, and 7 (2.0%) had cancer. Among 1420 total serrated class lesions and 3484 conventional adenomas ≥10 mm in size, the rate of cancer was 0.7% (10/1420) and 3.7% (128/3484), respectively.

Table 3 shows the results of the blinded review of lesion photographs to determine whether cancer was endoscopically evident prior to resection. Among the 28 cancers 10–19 mm in size, 3 had no endoscopic image available. Of the remaining 25 lesions, 13 (52.0%) had endoscopic changes indicating cancer, including ulceration, depression, and vascular disruption (Fig. 2), and 11 (44.0%) were considered to have no overt endoscopic features of cancer on review. Among 110 cancers ≥20 mm in size, 4 lesions had no endoscopic image available. Of the remaining 106 lesions, 84 (79.2%) were considered to have endoscopic features of cancer on review and 16 (15.1%) did not.

Table 4 shows the method of resection for the cancers. In the 10–19 mm sized group, among the 13 lesions that had endoscopic features of cancer on review of photographs (Fig. 2), 8 (61.5%) were treated by surgery and 5 (38.5%) were resected endoscopically (4 en bloc and 1 piecemeal). In the ≥20 mm group, among the 84 lesions that were endoscopically recognized as cancer on review of photographs, 80 (95.2%) were treated by surgery and 4 (4.8%) were resected endoscopically (all by piecemeal technique). Among the 16 lesions that were not recognized as cancer on review of photographic images, 14 (87.5%) were endoscopically resected and 2 (12.5%) were treated by surgery.
Discussion

This is the largest report of the prevalence of cancer in colorectal lesions 10–19 mm in size (▶Table 1). We found that the prevalence of cancer in colorectal lesions 10–19 mm and ≥20 mm was 0.9% and 6.0%, respectively. The higher cancer rate in lesions ≥20 mm compared with lesions 10–19 mm confirms that the risk of cancer increases with increasing lesion size [1–4]. We reviewed images of malignant lesions for morphological features of cancer, and found that endoscopic features of cancer were present in a higher percentage of lesions ≥20 mm in size compared with lesions of 10–19 mm (79.2% vs. 52.0%). Furthermore, we found a lower prevalence of cancer in serrated class lesions compared with conventional adenomas ≥10 mm in size (0.7% vs. 3.7%), which was consistent with previous observations [28].

Compared with older reports, we found a lower cancer rate in polyps 10–19 mm in size (▶Table 1). Prior to the current study, Shinya et al. reported the largest database on the prevalence of cancer in polyps of 10–19 mm, with a cancer rate of 4.6% in 2738 polyps in this size range [21].

The trend toward decreasing rates of cancer in polyps 10–19 mm may reflect the improved imaging capabilities of colonoscopes and an increasing emphasis on identification of flat lesions with a low risk of cancer [12–14]. In addition, our endoscopists have achieved adenoma detection rates (ADRs) well above recommended standards; indeed, the endoscopist with the largest case volume, who performed more than half of the colonoscopies in the unit during the study period, has achieved ADRs of about 50% in multiple previous studies [29–31]. Thus, high ADRs, combined with improved resolution of instruments, are likely to have led to detection of an array of flat and serrated lesions that would have escaped detection by the endoscopists using lower resolution instruments in older studies. Indeed, a trend of declining rates is evident when examining prevalence rates of cancer according to publication dates (▶Table 1) [2, 8, 16–27].

The strength of our study is the large size, which exceeds that of any previous study on this topic (▶Table 1). Limitations include the retrospective nature of the study, though the database was accumulated prospectively. Polyp size was estimated...
endoscopically, which can lead to errors in classification. We reviewed endoscopic images of malignant lesions retrospectively, and the findings of the review were consistent with the surgical vs. endoscopic management utilized at the time of diagnosis. Although pathological definitions of cancer have not changed over the study interval, classification of serrated lesions and awareness of sessile serrated polyps have evolved considerably [28, 32]. We have shown with our center that expert pathological review of lesions previously identified as "hyperplastic" frequently results in reclassification of the lesions as sessile serrated polyps. As we did not have the study lesions reviewed by expert pathologists, our data certainly underestimate the fraction of serrated lesions that are sessile serrated polyps and overestimate the fraction that are hyperplastic. However, the prevalence of cancer and the numbers of conventional adenomas vs. lesions in the serrated class should be accurate. Additionally, with regard to histology, during most of the study period, our pathologists did not report certain pathological features that are currently sometimes or always considered informative, such as depth of invasion and the presence or absence of tumor budding. Furthermore, we do not have long term follow-up data on cancer patients in our database. Finally, our center provides some tertiary services. We cannot exclude the possibility that cancers were over- or underrepresented because of referral bias. However, the majority of our cases do not reflect lesions referred for endoscopic resection.

Our results suggest that conventional adenomas are more likely to harbor cancer than serrated lesions of similar size. Serrated lesions have received considerable attention in recent decades and contribute disproportionately to interval cancers [33–34]. However, our data suggest that the risk per individual lesion is higher for conventional adenomas than for serrated lesions.

In conclusion, the prevalence of invasive cancer in colorectal lesions 10–19 mm in size is low at 0.9%, and lower than previously reported. About half of cancers in lesions of 10–19 mm are evident based on endoscopic features prior to resection, and cancer is less likely to be endoscopically evident compared with lesions ≥20 mm. Among all lesions ≥10 mm, cancer is more common in conventional adenomas than in serrated lesions of similar size.

Acknowledgment

This work was supported by a grant from Scott Schurz and his children of Bloomington, IN, to the Indiana University foundation in the name of Douglas K. Rex.

Competing interests

Dr. Rex is a consultant for Olympus Corp., Medtronic and Aries. He has consultancy and research support links with Boston Scientific and research support links with EndoAid, Olympus Corporation and Medivators. Ownership: Satis Corporation.

References


[29] Rex DK, Helbig CC. High yields of small and flat adenomas with high-definition colonoscopes using either white light or narrow band imaging. Gastroenterology 2007; 133: 42–47


[34] Sawhney MS, Farrar WD, Gudiseva S et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131: 1700–1705